References
  1. Laugesen K, Jørgensen JOL, Petersen I, Sørensen HT. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark.Eur J Endocrinol . 2019;181(3):267-273.
  2. Prescription cost analysis. England 2018. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018 Last accessed 3/7/20
  3. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med . 2005;353(16):1711-1723.
  4. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol . 2015;80(3):372-380.
  5. British National Formulary. Glucocorticoid and mineralocorticoid activity. https://bnf.nice.org.uk/treatment-summary/glucocorticoid-therapy.html Last accessed 3/7/20
  6. British National Formulary. Topical corticosteroids. https://bnf.nice.org.uk/treatment-summary/topical-corticosteroids.html Last accessed 3/7/20
  7. Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, Bulloch K, Cidlowski JA, de Kloet ER, Fardet L, Joëls M, Leung DY, McEwen BS, Roozendaal B, Van Rossum EF, Ahn J, Brown DW, Plitt A, Singh G. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171(10):1045-51.
  8. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
  9. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420-6.
  10. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res . 2000;15(6):993-1000.
  11. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van’t Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med . 1993;119(10):963-968.
  12. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, Isenberg DA. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis. 1992;51(2):152-5
  13. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-24.
  14. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–93.
  15. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med . 2004;141(10):764-770.
  16. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab . 1991;72(1):39-45.
  17. Chan S, Debono M. Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy. Ther Adv Endocrinol Metab . 2010;1(3):129-138. doi:10.1177/2042018810380214
  18. Streck, W.F.; Lockwood, D.H. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am. J. Med. 1979, 66, 910–914
  19. Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid Therapy and Adrenal Suppression. [Updated 2018 Oct 19]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279156/ Last accessed 3/7/20
  20. Jasani MK, Boyle JA, Greig WR, Dalakos TG, Browning MC, Thompson A, Buchanan WW. Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. Q J Med. 1967 Jul;36(143):261-76.
  21. Mendoza-Cruz, A.C.; Wargon, O.; Adams, S.; Tran, H.; Verge, C.F. Hypothalamic-pituitary-adrenal axis recovery following prolonged prednisolone therapy in infants. J. Clin. Endocrinol. Metab. 2013, 98, E1936–E1940.
  22. Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.Semin Arthritis Rheum . 2016;46(1):133-141.
  23. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab . 2015;100(6):2171-2180.
  24. Furst DE, Matteson EL, Ramirez Curtis M. Glucocorticoid withdrawal. https://www.uptodate.com/contents/glucocorticoid-withdrawal Last accessed 3/7/20
  25. NICE clinical knowledge summaries. Scenario: Management of polymyalgia rheumatica https://cks.nice.org.uk/polymyalgia-rheumatica#!scenarioRecommendation Last accessed 3/7/20
  26. Robson JC, Dawson J, Cronholm PF, Ashdown S, Easley E, Kellom KS, Gebhart D, Lanier G, Milman N, Peck J, Luqmani RA, Shea JA, Tomasson G, Merkel PA. Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.Rheumatol Int . 2018;38(4):675-682.
  27. Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. Renal transplant recipient attitudes toward steroid use and steroid withdrawal.Clin Transplant . 2003;17(2):135-139.
  28. Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab . 1993;76(5):1188-1191.
  29. Schuetz P, Christ-Crain M, Schild U, Süess E, Facompre M, Baty F, Nusbaumer C, Brutsche M, Müller B. Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med . 2008;8:1
  30. British National Formulary. Prednisolone. Treatment Cessation. https://bnf.nice.org.uk/drug/prednisolone.html#treatmentCessationInformation Last accessed 3/7/20
  31. Addison’s self-help group. Newly diagnosed – Sick day rules https://www.addisonsdisease.org.uk/newly-diagnosed-sick-day-rules Last accessed 3/7/20
  32. Giordano R, Guaraldi F, Mazzoli M, Ghigo E. Do glucocorticoids induce addiction in humans?. J Endocrinol Invest . 2017;40(8):881-883
  33. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003;24(4):523-38
  34. Fardet L, Nazareth I, Whitaker HJ, Petersen I: Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry 2013; 74:e281–e286
  35. Goldfarb EV, Sinha R. Drug-Induced Glucocorticoids and Memory for Substance Use. Trends Neurosci. 2018 Nov;41(11):853-868.
  36. Anfinson TJ, Channappa C, Vo HT. Drug dependence involving prednisone: two cases and a review of the literature. Psychopharmacol Bull. 2008;41(1):154-63.
  37. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int . 2008;82(4):249-257.
  38. NHS. Coping with side effects of steroid tablets. https://www.nhs.uk/conditions/steroid-tablets/#side-effects Last accessed 3/7/20
  39. NICE guideline [NG100] Rheumatoid arthritis in adults: management https://www.nice.org.uk/guidance/ng100/chapter/Recommendations#initial-pharmacological-management Last accessed 3/7/20
  40. NICE guideline [NG115] Chronic obstructive pulmonary disease in over 16s: diagnosis and management https://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease#path=view%3A/pathways/chronic-obstructive-pulmonary-disease/stable-copd-oral-therapy.xml&content=view-node%3Anodes-corticosteroids Last accessed 3/7/20
  41. Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005374.